Tunable Signal-Off and Signal-On Electrochemical Cisplatin Sensor

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We report the first electrochemical cisplatin sensor fabricated with a thiolated and methylene blue (MB)-modified oligo-adenine (A)-guanine (G) DNA probe. Depending on the probe coverage, the sensor can behave as a signal-off or signal-on sensor. For the high-coverage sensor, formation of intrastrand Pt(II)-AG adducts rigidifies the oligo-AG probe, resulting in a concentration-dependent decrease in the MB signal. For the low-coverage sensor, the increase in probe-to-probe spacing enables binding of cisplatin via the intrastrand GNG motif (N = A), generating a bend in the probe which results in an increase in the MB current. Although both high-coverage signal-off and low-coverage signal-on sensors are capable of detecting cisplatin, the signal-on sensing mechanism is better suited for real time analysis of cisplatin. The low-coverage sensor has a lower limit of detection, wider optimal AC frequency range, and faster response time. It has high specificity for cisplatin and potentially other Pt(II) drugs and does not cross-react with satraplatin, a Pt(IV) prodrug. It is also selective enough to be employed directly in 50% saliva and 50% urine. This detection strategy may offer a new approach for sensitive and real time analysis of cisplatin in clinical samples.

Original languageEnglish (US)
Pages (from-to)9984-9989
Number of pages6
JournalAnalytical chemistry
Volume89
Issue number18
DOIs
StatePublished - Sep 19 2017

Fingerprint

Electrochemical sensors
Cisplatin
Methylene Blue
Sensors
DNA Probes
Prodrugs
Guanine
Adenine
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Analytical Chemistry

Cite this

Tunable Signal-Off and Signal-On Electrochemical Cisplatin Sensor. / Wu, Yao; Lai, Rebecca Y.

In: Analytical chemistry, Vol. 89, No. 18, 19.09.2017, p. 9984-9989.

Research output: Contribution to journalArticle

@article{644a0a3991444f44917494af15c1372e,
title = "Tunable Signal-Off and Signal-On Electrochemical Cisplatin Sensor",
abstract = "We report the first electrochemical cisplatin sensor fabricated with a thiolated and methylene blue (MB)-modified oligo-adenine (A)-guanine (G) DNA probe. Depending on the probe coverage, the sensor can behave as a signal-off or signal-on sensor. For the high-coverage sensor, formation of intrastrand Pt(II)-AG adducts rigidifies the oligo-AG probe, resulting in a concentration-dependent decrease in the MB signal. For the low-coverage sensor, the increase in probe-to-probe spacing enables binding of cisplatin via the intrastrand GNG motif (N = A), generating a bend in the probe which results in an increase in the MB current. Although both high-coverage signal-off and low-coverage signal-on sensors are capable of detecting cisplatin, the signal-on sensing mechanism is better suited for real time analysis of cisplatin. The low-coverage sensor has a lower limit of detection, wider optimal AC frequency range, and faster response time. It has high specificity for cisplatin and potentially other Pt(II) drugs and does not cross-react with satraplatin, a Pt(IV) prodrug. It is also selective enough to be employed directly in 50{\%} saliva and 50{\%} urine. This detection strategy may offer a new approach for sensitive and real time analysis of cisplatin in clinical samples.",
author = "Yao Wu and Lai, {Rebecca Y.}",
year = "2017",
month = "9",
day = "19",
doi = "10.1021/acs.analchem.7b02353",
language = "English (US)",
volume = "89",
pages = "9984--9989",
journal = "Analytical Chemistry",
issn = "0003-2700",
publisher = "American Chemical Society",
number = "18",

}

TY - JOUR

T1 - Tunable Signal-Off and Signal-On Electrochemical Cisplatin Sensor

AU - Wu, Yao

AU - Lai, Rebecca Y.

PY - 2017/9/19

Y1 - 2017/9/19

N2 - We report the first electrochemical cisplatin sensor fabricated with a thiolated and methylene blue (MB)-modified oligo-adenine (A)-guanine (G) DNA probe. Depending on the probe coverage, the sensor can behave as a signal-off or signal-on sensor. For the high-coverage sensor, formation of intrastrand Pt(II)-AG adducts rigidifies the oligo-AG probe, resulting in a concentration-dependent decrease in the MB signal. For the low-coverage sensor, the increase in probe-to-probe spacing enables binding of cisplatin via the intrastrand GNG motif (N = A), generating a bend in the probe which results in an increase in the MB current. Although both high-coverage signal-off and low-coverage signal-on sensors are capable of detecting cisplatin, the signal-on sensing mechanism is better suited for real time analysis of cisplatin. The low-coverage sensor has a lower limit of detection, wider optimal AC frequency range, and faster response time. It has high specificity for cisplatin and potentially other Pt(II) drugs and does not cross-react with satraplatin, a Pt(IV) prodrug. It is also selective enough to be employed directly in 50% saliva and 50% urine. This detection strategy may offer a new approach for sensitive and real time analysis of cisplatin in clinical samples.

AB - We report the first electrochemical cisplatin sensor fabricated with a thiolated and methylene blue (MB)-modified oligo-adenine (A)-guanine (G) DNA probe. Depending on the probe coverage, the sensor can behave as a signal-off or signal-on sensor. For the high-coverage sensor, formation of intrastrand Pt(II)-AG adducts rigidifies the oligo-AG probe, resulting in a concentration-dependent decrease in the MB signal. For the low-coverage sensor, the increase in probe-to-probe spacing enables binding of cisplatin via the intrastrand GNG motif (N = A), generating a bend in the probe which results in an increase in the MB current. Although both high-coverage signal-off and low-coverage signal-on sensors are capable of detecting cisplatin, the signal-on sensing mechanism is better suited for real time analysis of cisplatin. The low-coverage sensor has a lower limit of detection, wider optimal AC frequency range, and faster response time. It has high specificity for cisplatin and potentially other Pt(II) drugs and does not cross-react with satraplatin, a Pt(IV) prodrug. It is also selective enough to be employed directly in 50% saliva and 50% urine. This detection strategy may offer a new approach for sensitive and real time analysis of cisplatin in clinical samples.

UR - http://www.scopus.com/inward/record.url?scp=85029575286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029575286&partnerID=8YFLogxK

U2 - 10.1021/acs.analchem.7b02353

DO - 10.1021/acs.analchem.7b02353

M3 - Article

C2 - 28799328

AN - SCOPUS:85029575286

VL - 89

SP - 9984

EP - 9989

JO - Analytical Chemistry

JF - Analytical Chemistry

SN - 0003-2700

IS - 18

ER -